711P Nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy

Laurence Albigès, Nizar M. Tannir, Mauricio Burotto, David F. McDermott, Elizabeth R. Plimack, Philippe Barthélémy, Camillo Porta, T.B. Powles, Frede Donskov, Saby George, Christian Kollmannsberger, Howard Gurney, Marc‐Oliver Grimm, Yoshihiko Tomita, D. Castellano Gauna, Brian I. Rini, Toni K. Choueiri, Shruti Shally Saggi, M. Brent McHenry, Robert J. Motzer